Understanding how HER2 mutations affect treatment responses in lung cancer
Official title: Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer
Funded at University of Tx Md Anderson Can Ctr · NIH-11130408 · Data updated 2026-11-12
This study is looking at how different changes in the HER2 gene affect how well people with non-small cell lung cancer respond to specific treatments, so we can find the best options for each type of mutation and understand why some tumors stop responding to these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $695,004 |
| NIH project number | 1R01CA287279-01A1 |
| Project ID | NIH-11130408 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with HER2-mutant non-small cell lung cancer.
✕Less likely to help
Patients without HER2 mutations or those with other types of lung cancer may not benefit from this research.
What this research studies
This research investigates the structural differences in HER2 mutations that affect how patients with non-small cell lung cancer (NSCLC) respond to targeted therapies. By analyzing over 80 different mutations, the study aims to identify which specific HER2 inhibitors are most effective for each mutation type. The research also explores how tumors develop resistance to these treatments, which can occur through additional mutations or other mechanisms. This comprehensive approach seeks to improve treatment selection for patients with HER2-mutant cancers.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with HER2-mutant lung cancer.
How similar studies have gone: While there has been some success in targeting HER2 in other cancers, this specific approach for HER2-mutant NSCLC is relatively novel and untested.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Heymach, John V. — University of Tx Md Anderson Can Ctr
- Study coordinator: Heymach, John V.
Related research
Other NIH-funded projects on the same topics.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
-
Modeling tumor differences to guide new treatments for resistant small cell lung cancer
A study aims to understand why some small cell lung cancer tumors resist treatment and use those insights to develop new targeted therapies.
-
TP53-mutant NSCLC: how epigenetic viral mimicry could boost immune therapy
A research grant exploring how p53 mutations in non-small cell lung cancer affect responses to a viral mimicry-based epigenetic therapy, with the goal of improving immune therapy outcomes for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.